Literature DB >> 12077084

Ileal Crohn's disease is best treated by surgery.

M J G Farthing1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12077084      PMCID： PMC1773279          DOI： 10.1136/gut.51.1.13

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  28 in total

Review 1.  Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there?

Authors:  L R Sutherland
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

2.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

3.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.

Authors:  H Lochs; M Mayer; W E Fleig; P B Mortensen; P Bauer; D Genser; W Petritsch; M Raithel; R Hoffmann; V Gross; M Plauth; M Staun; L B Nesje
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

4.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J M Willoughby; J Beckett; P J Kumar; A M Dawson
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

5.  A controlled trial of azathioprine in Crohn's disease.

Authors:  J L Rosenberg; B Levin; A J Wall; J B Kirsner
Journal:  Am J Dig Dis       Date:  1975-08

6.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

7.  Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.

Authors:  C Prantera; M Cottone; F Pallone; V Annese; A Franzè; R Cerutti; G Bianchi Porro
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

8.  Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.

Authors:  D P O'Donoghue; A M Dawson; J Powell-Tuck; R L Bown; J E Lennard-Jones
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

9.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.

Authors:  D H Present; B I Korelitz; N Wisch; J L Glass; D B Sachar; B S Pasternack
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

10.  Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.

Authors:  S Bar-Meir; Y Chowers; A Lavy; D Abramovitch; A Sternberg; G Leichtmann; R Reshef; S Odes; M Moshkovitz; R Bruck; R Eliakim; E Maoz; U Mittmann
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.